The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition

References

• Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–578.
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Adverse side-effects to biological agents. Allergy Eur J Allergy Clin Immunol. 2006;61(8):912–920.
   Google Scholar
• Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr (Engl Ed). 2018;109(9):791–800.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sato K, Takagi A, et al. Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol. 2018;45(11):e325–e326.
   PubMed Web of Science ®Google Scholar
• Sadik CD, Thieme M, Zillikens D, et al. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol. 2019;33(11):e406–e407.
   PubMed Web of Science ®Google Scholar
• Tan TL, Taglia L, Yazdan P. Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy. J Cutan Pathol. 2021;48(6):771–774. Epub ahead of print January 2021.
   PubMed Web of Science ®Google Scholar
• Kurtipek GS, Zekey E, Akyurek FT, et al. Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis. Dermatol Ther. 2020;33:e13346.
   PubMed Web of Science ®Google Scholar
• Honma M, Nozaki H, Hayashi K, et al. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab. J Dermatol. 2019;46(12):e468–e469.
   PubMed Web of Science ®Google Scholar
• Abbruzzese A, Venerito V, Lopalco G, et al. Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment. J Clin Rheumatol. 2020;26(6):e208–e209. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Tadiotto Cicogna G, Messina F, Nalotto L, et al. Case report: paradoxical acrodermatitis of hallopeau-like eruption following anti-IL-17 therapy. F1000Res. 2019;8:336.
   PubMedGoogle Scholar
• Currado D, Margiotta D, Conforti C, et al. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scand J Rheumatol. 2020;49(1):75–76.
   PubMed Web of Science ®Google Scholar
• Sladden MJ, Sladden CS, Gulliver WPF. Secukinumab-induced psoriasiform eruption. JAMA Dermatol. 2017;153(11):1194–1195.
   PubMed Web of Science ®Google Scholar
• Noell C, McQuade B, Gottlieb A, et al. Anti IL-17 flared psoriasis in a patient on secukinumab. Dermatol Ther. 2017;30:2–3.
   Web of Science ®Google Scholar
• Hoshina D, Haga N, Furuya K, et al. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab. Clin Exp Dermatol. 2018;43(6):718–719.
   PubMed Web of Science ®Google Scholar
• Dogra S, Bishnoi A, Narang T, et al. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2019;44(1):72–73.
   PubMed Web of Science ®Google Scholar
• Mossner R, Pinter A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol. 2020;30(2):177–178.
   Web of Science ®Google Scholar
• Durmaz K, Ataseven A, Ozer I. Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient. Dermatol Ther. 2020;33(4):e13504.
   PubMed Web of Science ®Google Scholar
• EL-Komy M, Amer M, Mostafa A, et al. Secukinumab retreatment associated psoriasis flare with pustules. J Dermatolog Treat. 2022;33:1107–1110.
   Google Scholar
• Penalba-Torres M, Rivera-Díaz R. Palmoplantar pustulosis under secukinumab in two patients without psoriasis. J Dtsch Dermatol Ges. 2022;20(1):106–109.
   Web of Science ®Google Scholar
• Hosokawa Y, Hamada T, Ashida H, et al. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction. J Dermatol. 2019;46(8):e302–e303.
   PubMed Web of Science ®Google Scholar
• Kashlan R, Slater K, Garber ME, et al. Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab. JAAD Case Rep. 2021;10:47–49.
   PubMedGoogle Scholar
• Caravello S, Moggio E, Soglia S, et al. Paradoxical reaction to Brodalumab in a patient affected by psoriasis. Ital J Dermatol Venereol. 2021;156(4):511–512.
   PubMedGoogle Scholar
• Martínez-Doménech Á, García-Legaz-Martínez M, Magdaleno-Tapial J, et al. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis. Dermatol Online J. 2019;25:0–2.
   Google Scholar
• Oiwa T, Fujita M, Takase S, et al. A case of ixekizumab-induced psoriasiform eruption. Acta Derm Venereol. 2019;99(4):446–447.
   PubMed Web of Science ®Google Scholar
• Vidal D, Ros S, Reina D. Paradoxical arthritis due to ixekizumab in a patient with plaque psoriasis. Actas Dermosifiliogr (Engl Ed). 2019;110(3):255–256.
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, De Simone C, et al. Multiple paradoxical reactions during ixekizumab therapy. Dermatol Ther. 2019;32(3):e12852.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Feb 29. Identifier NCT01406938, Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE); 2015 May 19 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01406938.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Feb 29. Identifier NCT01101100, Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis; 2010 Apr 09 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01101100.
   Google Scholar
• Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25.
   PubMed Web of Science ®Google Scholar
• Al-Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1440–1448.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;0:1.
   Google Scholar
• Burlando M, Cozzani E, Russo R, et al. Atopic-like dermatitis after secukinumab injection: a case report. Dermatol Ther. 2019;32(1):e12751.
   PubMed Web of Science ®Google Scholar
• Eichhoff G. Secukinumab-induced pompholyx in a psoriasis patient. Dermatol Online J. 2020;26(4):26.
   Google Scholar
• Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol. 2021;13(2):336–339.
   PubMed Web of Science ®Google Scholar
• Peera M, Smith A. Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: a case series. JAAD Case Rep. 2021;13:46–48.
   PubMedGoogle Scholar
• Miyagawa F, Fukuda K, Mori A, et al. Recurrence of secukinumab-induced eczematous eruptions after guselkumab treatment for pustular psoriasis. J Dermatol. 2021;48(10):E498–E499. Epub ahead of print July 2021.
   PubMed Web of Science ®Google Scholar
• Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in psoriasis patients under anti-IL-17A: does IL-22 play a key role? Clin Exp Dermatol. Epub ahead of print December 2021.
   Web of Science ®Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Phung M, Ighani A, et al. Ixekizumab (interleukin 17A antagonist): 12-week efficacy and safety outcomes in real-world clinical practice. J Cutan Med Surg. 2019;23(2):174–177.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-Severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447.
   PubMed Web of Science ®Google Scholar
• Rivera R, Velasco M, Vidal D, et al. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a spanish multicentre retrospective study. Dermatol Ther. 2020;33:e14066.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
   PubMed Web of Science ®Google Scholar
• Munera-Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol. 2019;33(1):e40–e42.
   PubMed Web of Science ®Google Scholar
• Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855–861.
   PubMed Web of Science ®Google Scholar
• Teraki Y, Takahashi A, Inoue Y, et al. Eyelid dermatitis as a side effect of interleukin-17A inhibitors in psoriasis. Acta Derm Venereol. 2018;98(4):456–457.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Gallo L, Patruno C, et al. Eczematous reaction to ixekizumab successfully treated with dupilumab. Dermatol Ther. 2020;33(2):e13218.
   PubMed Web of Science ®Google Scholar
• Satoh M, Yamamoto T. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis. Dermatol Ther. 2020;33(3):e13332.
   PubMed Web of Science ®Google Scholar
• Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20904561.
   PubMed Web of Science ®Google Scholar
• Oiwa T, Honda T, Otsuka A, et al. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors. J Eur Acad Dermatol Venereol. 2018;32(4):e122–e123.
   PubMed Web of Science ®Google Scholar
• Danset M, Hacard F, Jaulent C, et al. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal. Eur J Dermatol. 2020;30(6):741–743.
   PubMed Web of Science ®Google Scholar
• Kimura R, Sugita K, Yamamoto O. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema. Eur J Dermatol. 2020;30(6):732–734.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT03344640,Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy; 2017 Nov 17 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03344640.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01555125, First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE); 2012 Mar 15 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01555125.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02559622, Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA); 2015 Sep 24 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02559622.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis; 2012 Jul 16 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01640951.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02409667, Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE); 2015 Apr 07 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02409667.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT03066609, Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis; 2017 Feb 28 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03066609.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01636687, Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE); 2012 Jul 10 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01636687.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01392326, Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1); 2011 Jul 12 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01392326.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01806597, Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE); 2013 Mar 07 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01806597.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02008890, Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab; 2013 Dec 11 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02008890.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02474069, Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN); 2015 Jun 17 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02474069.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01132612, AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis; 2010 May 28 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01132612.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01365455, Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE); 2011 Jun 3 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01365455.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01358175, 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE 1); 2011 May 23 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01358175.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01412944, Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE); 2011 Aug 9 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01412944.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT00685399, Safety and Efficacy of AIN457 in Noninfectious Uveitis; 2008 May 28 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00685399.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01961609, Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE); 2013 Oct 11 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01961609.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02159053, 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4); 2014 Jun 9 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02159053.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01807520, Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE); 2013 Mar 8 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01807520.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02294227, 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4); 2014 Nov 19 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02294227.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02074982, Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis; 2014 Mar 3 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02074982.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01770379, Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (REASSURE2); 2013 Jan 17 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01770379.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT00771030, Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis; 2008 Oct 10 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00771030.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT00975637, Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis; 2009 Sep 11 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00975637.
   Google Scholar
• Brunner PM, Conrad C, Vender R, et al. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. Br J Dermatol. 2021;185(4):865–867.
   PubMed Web of Science ®Google Scholar
• Jin K, Matsuzaki Y, Akasaka E, et al. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. 2019;46(3):e108–e109.
   PubMed Web of Science ®Google Scholar
• Wollina U, Schonlebe J, Furll C. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. Dermatol Ther. 2020;33(1):e13161.
   PubMed Web of Science ®Google Scholar
• Pollack IR, Wolner ZJ, Hammett J, et al. Pyoderma gangrenosum in a patient on ixekizumab. JAAD Case Rep. 2021; 16:152–154.
   PubMedGoogle Scholar
• Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018;29(5):441–449.
   PubMed Web of Science ®Google Scholar
• Navarro-Triviño FJ, Sanchez-Parera R, Ruiz-Villaverde R. Secukinumab-induced paradoxical hidradenitis suppurativa. Dermatol Ther. 2020;33:1–3.
   Web of Science ®Google Scholar
• Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: Friends or foes? JAAD Case Rep. 2019;5(2):184–187.
   PubMedGoogle Scholar
• Babino G, D’Ambra I, Fulgione E, et al. Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab. Int J Dermatol. 2021;61(2):e79–e80.
   PubMed Web of Science ®Google Scholar
• Leccese P, Alpsoy E. Behçet’s disease: an overview of etiopathogenesis. Front Immunol. 2019;10:1067. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced behçet’s syndrome: a report of two cases. Oxford Med Case Reports. 2019;2019:239–241.
   Google Scholar
• Di Scala G, Bettiol A, Cojan RD, et al. Efficacy of the anti-IL 17 secukinumab in refractory behcet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108–113.
   PubMed Web of Science ®Google Scholar
• Grimaux X, Leducq S, Goupille P, et al. [Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease]. Ann Dermatol Venereol. 2018;145(11):676–682.
   PubMed Web of Science ®Google Scholar
• Shiga H, Fukuda S, Iijima K. Interleukin-17A inhibitor-induced crohn’s disease/behcet’s disease-like lesions. Inflamm Bowel Dis. 2017;23(6):E38–E39.
   PubMed Web of Science ®Google Scholar
• Barrado-Solis N, Rodrigo-Nicolas B, De la Morena-Barrio I, et al. Report of two cases of behcet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol JEADV. 2020;34(10):e587–e589.
   PubMed Web of Science ®Google Scholar
• Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ, et al. Behçet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges. 2021;19(1):116–118.
   Web of Science ®Google Scholar
• Chen D, Zhou M, Xu A, et al. Behcet’s-like disease in a patient treated with ixekizumab for chronic plaque psoriasis. Scand J Rheumatol. 2022;1–2.
   PubMed Web of Science ®Google Scholar
• Mease P, Roussou E, Burmester G-R, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367–378.
   PubMed Web of Science ®Google Scholar
• Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019;40(6):470–473.
   PubMed Web of Science ®Google Scholar
• Chitnavis M, Stein DJ, Commins S, et al. First-dose anaphylaxis to infliximab: a case of mammalian meat allergy. J Allergy Clin Immunol Pract. 2017;5(5):1425–1426.
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther. 2020;33(3):e13313.
   PubMed Web of Science ®Google Scholar
• Foley P, Tsai T-F, Rodins K, et al. Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East Regions: results from the REALIA study. Dermatol Ther (Heidelb). 2022;12(2):511–527.
   PubMed Web of Science ®Google Scholar
• Sébastien R, Claire V, Thierry V, et al. Secukinumab-induced acute autoimmune hemolytic anemia. Ann Pharmacother. 2020;54(9):933–934.
   PubMed Web of Science ®Google Scholar
• Nakahara T, Konishi S, Yasukochi Y, et al. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab. J Dermatol. 2019;46(5):e157–e158.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Cho C-S, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol (Hoboken, NJ). 2014;66(7):1693–1704.
   PubMed Web of Science ®Google Scholar
• Lindberg MR, Todd SP, Bunker DR, et al. Ixekizumab-induced serum sickness (like reaction): an unusual adverse effect. J Clin Rheumatol. 2021;27(8S):S469–S470. Epub ahead of print December
   PubMed Web of Science ®Google Scholar
• Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. Handb Exp Pharmacol. 2010;(196):29–55.
   Google Scholar
• Shibata M, Sawada Y, Yamaguchi T, et al. Drug eruption caused by secukinumab. Eur J Dermatol. 2017;27(1):67–68.
   PubMed Web of Science ®Google Scholar
• Peigottu MF, Montesu MA. Adverse skin reaction to secukinumab. J Eur Acad Dermatol Venereol. 2017;31(10):e432–e433.
   PubMed Web of Science ®Google Scholar
• Wong SCT, Chung HY. Secukinumab-induced delayed-type drug hypersensitivity reactions. JCR J Clin Rheumatol. 2019; 0:1.
   Google Scholar
• Darrigade A-S, Dendooven E, Mangodt E, et al. Delayed-type hypersensitivity to secukinumab with tolerance to ixekizumab. J Allergy Clin Immunol Pract. 2020;8(10):3626–3628.
   PubMed Web of Science ®Google Scholar
• Wong SCT, Chung HY. Secukinumab-induced delayed-type drug hypersensitivity reactions. J Clin Rheumatol. June 2019;26(6):e197–e198.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02029495, Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1); 2014 Jan 08 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02029495.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02745080, Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1); 2016 Apr 20 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02745080.
   Google Scholar
• Al-Johani KA, Fedele S, Porter SR. Erythema multiforme and related disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(5):642–654.
   PubMed Web of Science ®Google Scholar
• Conforti C, Currado D, Vezzoni R, et al. Erythema multiforme induced by secukinumab: Clinical, dermoscopic, and histological features. J Clin Rheumatol. 2021;27(5):e177–e178. Epub ahead of print January
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02696785, A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V); 2016 Mar 02 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02696785.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT02513550, A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P); 2015 Jul 31 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02513550.
   Google Scholar
• Mourad AA, Boktor MN, Yilmaz-Demirdag Y, et al. Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol. 2015;115(2):143–146.
   PubMed Web of Science ®Google Scholar
• Bekkali N, Simon C, Binois R, et al. [Severe urticaria with recurrence complicated by angioedema under secukinumab: a case report]. Therapie. 2020;75(5):509–511.
   PubMedGoogle Scholar
• Donzier L, Deschamps T, Pralong P, et al. Immediate hypersensitivity reaction to ixekizumab in a patient with psoriasis. J Eur Acad Dermatol Venereol. 2021;35(1):e18–e19. Epub ahead of print June
   PubMed Web of Science ®Google Scholar
• Galica K, Lesiak A, Ciążyńska M, et al. Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study. Postepy Dermatol Alergol. 2021;38(6):973–978.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01708603, P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2); 2012 Oct 17 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01708603.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01474512, A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1); 2011 Nov 18 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01474512.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01358578, Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE); 2011 May 23 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01358578.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01624233, A Study in Japanese Participants With Moderate-to-Severe Psoriasis (UNCOVER-J); 2012 Jun 20 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01624233.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01952015, Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP); 2013 Sep 27 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01952015.
   Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy Eur J Allergy Clin Immunol. 2020;75(2):423–432.
   Google Scholar
• Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108(2):123–124.
   PubMed Web of Science ®Google Scholar
• Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33(9):1733–1741.
   PubMed Web of Science ®Google Scholar
• Wehrmann C, Sondermann W, Körber A. [Secukinumab-induced subacute-cutaneous lupus erythematosus]. Hautarzt. 2018;69(1):64–66.
   PubMed Web of Science ®Google Scholar
• Chatzimichail G, Zillikens D, Thaçi D. Secukinumab-induced chronic discoid lupus erythematosus. JAAD Case Rep. 2020;6(4):362–364.
   PubMedGoogle Scholar
• Conforti C, Retrosi C, Giuffrida R, et al. Secukinumab-induced subacute cutaneous lupus erythematosus. Dermatol Ther. 2020;33(3):e13417.
   PubMed Web of Science ®Google Scholar
• Kaler J, Kaeley GS. Secukinumab-induced lupus erythematosus: a case report and literature review. J Clin Rheumatol. 2020;27:S753–S754.
   Web of Science ®Google Scholar
• Ang E, Hadjieconomou S, Kalavala M. Brodalumab-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2021;46(5):926–927.
   PubMed Web of Science ®Google Scholar
• Koller-Smith L, Oakley S. Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis. Rheumatology (Oxford). 2021.
   PubMedGoogle Scholar
• Anthony E, Rajgopal Bala H, Goh MSY, et al. Ixekizumab-treatment-emergent photosensitive cutaneous eruption. Australas J Dermatol. 2018;59(4):e284–e286.
   PubMed Web of Science ®Google Scholar
• Prieto-Barrios M, Rodriguez-Peralto JL, Vico-Alonso C, et al. Injection-site reaction to ixekizumab histologically mimicking lupus tumidus: report of two cases. Indian J Dermatol Venereol Leprol. 2018;84(5):610–613.
   PubMed Web of Science ®Google Scholar
• Satoh Y, Nakano K, Yoshinari H, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus. 2018;27(7):1202–1206.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT04181762, Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE); 2019 Nov 29 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04181762.
   Google Scholar
• Bonomo L, Ghoneim S, Levitt J. A case of granuloma annulare associated with secukinumab use. Case Rep Dermatol Med. 2017;2017:1–4.
   Google Scholar
• Clark ML, Tobin CA, Sutton A, et al. Granuloma annulare in the setting of secukinumab. Case Rep Dermatol Med. 2018; 2018:5175319–5175313.
   PubMedGoogle Scholar
• Fässler M, Schlapbach C. Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab. JAAD Case Rep. 2020;6(9):832–834.
   PubMedGoogle Scholar
• Fox JD, Aramin H, Ghiam N, et al. Secukinumab-associated localized granuloma annulare (Saga): a case report and review of the literature. Dermatol Online J. 26(8).
   Google Scholar
• Gray AR, Davies OMT, White K, et al. Granuloma annulare following initiation of interleukin-17a antagonist. Clin Exp Dermatol. 2021;46(5):924–926. Epub ahead of print January
   PubMed Web of Science ®Google Scholar
• Nyckowski T, Ceilly R, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. Skin. 2017;1(2):95–99.
   Google Scholar
• Hornick N, Wang A, Lim Y, et al. Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis. J Eur Acad Dermatol Venereol. 2020;34(10):e583–e585. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hatipoglu D, Tanski C, Hachamovitch R, et al. Ixekizumab-Induced cardiac sarcoidosis: a case report. CJC Open. 2021;3(1):118–120.
   PubMedGoogle Scholar
• Lu J-W, Zhang M-H, Gopee S, et al. Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis. J Dermatol. 2021;48(10):E494–E495. Epub ahead of print July
   PubMed Web of Science ®Google Scholar
• Kirby C, Herlihy D, Clarke L, et al. Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis. BMJ Case Rep. 2021;14(2):e240615.
   PubMedGoogle Scholar
• Sambharia M, Magge T, Ramakrishna S. Worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox. Chest. 2018;154(4):898A.
   Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2020;33(6):e14202.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Feb 29. Identifier NCT01649375, 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2); 2012 Jul 25 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01649375.
   Google Scholar
• Wang A, Hornick N, Lim Y, et al. IL-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis. J Eur Acad Dermatol Venereol. 2020;34(9):e497–e499.
   PubMed Web of Science ®Google Scholar
• Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis. Clin Exp Dermatol. 2020;45(4):455–456. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220–e221.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018;32(1):e32–e34.
   PubMed Web of Science ®Google Scholar
• Hayashida MZ, Pinheiro JRS, Enokihara MMS, e S. Biologic therapy-induced pemphigus. An Bras Dermatol. 2017;92(4):591–593.
   PubMed Web of Science ®Google Scholar
• Ohata C, Shimizu Y, Hayashi M. Pemphigus foliaceus in a patient with psoriasis treated with brodalumab. J Dermatol. 2020;47(12):e455–e457.
   PubMed Web of Science ®Google Scholar
• Morishima-Koyano M, Nobeyama Y, Fukasawa-Momose M, et al. Case of pemphigus foliaceus misdiagnosed as a single condition of erythrodermic psoriasis and modified by brodalumab. J Dermatol. 2020;47(5):e201–e202.
   PubMed Web of Science ®Google Scholar
• Yalici Armagan B, Atakan N. New onset alopecia areata during secukinumab therapy. Dermatol Ther. 2019;32:1–2.
   Web of Science ®Google Scholar
• Yajima M, Akeda T, Kondo M, et al. Alopecia diffusa while using interleukin-17 inhibitors against psoriasis vulgaris. Case Rep Dermatol. 2019;11(1):82–85.
   PubMed Web of Science ®Google Scholar
• Akdogan N, Gokoz O. Ixekizumab-induced alopecia with folliculitis decalvans-like presentation. Dermatol Ther . 2021;34(2):e14784.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Nia JK, Hashim PW, et al. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res. 2018;310(8):607–614.
   PubMed Web of Science ®Google Scholar
• Sacchelli L, Magnano M, Patrizi A, et al. Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: a case of serendipity or zemblanity? Dermatol Ther. 2019;32:3–5.
   Web of Science ®Google Scholar
• Rongioletti F, Mugheddu C, Murgia S. Repigmentation and new growth of hairs after anti-interleukin-17 therapy with secukinumab for psoriasis. JAAD Case Rep. 2018;4(5):486–488.
   PubMedGoogle Scholar
• Mashima E, Sawada Y, Yamaguchi T, et al. Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration. Eur J Dermatol. 2018;28(4):539–540.
   PubMed Web of Science ®Google Scholar
• Sánchez-Dueñas LE, Rojano-Fritz LK, García-Rodríguez JC. Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis. JAAD Case Rep. 2020;6(7):683–685.
   PubMedGoogle Scholar
• Thompson JM, Cohen LM, Yang CS, et al. Severe, ulcerative, lichenoid mucositis associated with secukinumab. JAAD Case Rep. 2016;2(5):384–386.
   PubMedGoogle Scholar
• Komori T, Honda T, Endo Y, et al. Oral lichen planus associated with candidiasis during secukinumab treatment. J Dermatol. 2017;44(4):e60–e61.
   PubMed Web of Science ®Google Scholar
• Capusan TM, Herrero-Moyano M, Martínez-Mera CR, et al. Oral lichenoid reaction in a psoriatic patient treated with secukinumab: a drug-related rather than a class-related adverse event? JAAD Case Rep. 2018;4(6):521–523.
   PubMedGoogle Scholar
• Maglie R, Di Cesare A, Lazzeri L, et al. Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment. Br J Dermatol. 2018;178(1):303–304.
   PubMed Web of Science ®Google Scholar
• Farah CS. Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy. Aust Dent J. 2021;66(3):340–345.
   PubMed Web of Science ®Google Scholar
• Ghiam N, Ojong O, Vasile G, et al. Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis. Dermatol Online J. 26(12).
   Google Scholar
• Reverte M, Etienne M, Fouchard M, et al. Occurrence of Henoch–Schönlein purpura in a patient treated with secukinumab. J Eur Acad Dermatology Venereol. 2019;33:e455–e457.
   PubMed Web of Science ®Google Scholar
• Villani A, De Fata Salvatores G, Nappa P, et al. Cutaneous leucocytoclastic vasculitis during secukinumab treatment. Ital J Dermatol Venereol. 2021;156:9–10.
   PubMedGoogle Scholar
• Chelli C, Loget J, Vanhaecke C, et al. Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis. Acta Derm Venereol. 2020;100(6):adv00077.
   PubMedGoogle Scholar
• da Silva Cendon Duran C, Barreto Santiago M. Cutaneous vasculitis during secukinumab treatment. Eur J Case Reports Intern Med. 2020;7:1815.
   Google Scholar
• Bostan E, Gulseren D, Yalici-Armagan B, et al. Vasculitis during certolizumab pegol and secukinumab treatment: report of two cases. Dermatol Ther. 2021;34(4):e15007.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT01892436, Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext); 2013 Jul 04 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01892436.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT01646177, A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3); 2012 Jul 20 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01646177.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT01199302, Long-term Safety Study of Brodalumab in Adults With Crohn’s Disease; 2010 Sep 10 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01199302.
   Google Scholar
• Kobak S. Secukinumab-induced Raynaud’s phenomenon: first report in the literature. Ther Adv Drug Saf. 2020;11:2042098620905976.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT01169844, Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis; 2010 Jul 26 [cited 2022 Mar 28]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01169844.
   Google Scholar
• Mery-Bossard L, Bagny K, Chaby G, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31(1):181–186.
   PubMed Web of Science ®Google Scholar
• Nieto-Benito LM, Baniandrés-Rodríguez O. New-onset vitiligo during treatment with secukinumab: report of two cases and review of the literature. Clin Drug Investig. 2020;40(11):1089–1091.
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, et al. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34:e15102.
   PubMed Web of Science ®Google Scholar
• Eker H, Kaya İslamoğlu ZG, Demirbaş A. Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab. Dermatol Therapy. 2022;35:e15314.
   PubMed Web of Science ®Google Scholar
• Giordano D, Magri F, Persechino F, et al. Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: a case report. Case Rep Dermatol. 2021;13(1):209–215.
   PubMed Web of Science ®Google Scholar
• María PS, Valenzuela F, Morales C, et al. Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature. Dermatol Rep. 2017;9:43–45.
   Web of Science ®Google Scholar
• Zhang S, Liang J, Tian X, et al. Secukinumab-induced multiple lentigines in areas of resolved psoriatic plaques: a case report and literature review. Dermatol Ther. 2021;34:e15048.
   PubMed Web of Science ®Google Scholar
• Purnell JC, Williams BA, Shalin SC, et al. Mucocutaneous findings associated with interleukin (IL)-17 inhibition. JAAD Case Rep. 2016;2(1):92–94.
   PubMedGoogle Scholar